Community Stories that Inspire
Stay informed with the latest updates from the GLP-1 community, including heartfelt stories of resilience and transformation, advocacy efforts, and news on affordability. Explore how these personal journeys and initiatives are driving awareness and making GLP-1 treatments more accessible for all. Click the button below to share your story and help normalize the use of GLP-1s.
Food Noise, Hashimoto’s & Insurance Hurdles
Denied, delayed, and dismissed—her battle with food noise, Hashimoto’s Disease, and weight fluctuations seemed endless until she found relief with GLP-1 medication. But just as she regained control, insurance barriers and shortages ripped it away, leaving her trapped in a cycle of frustration and uncertainty. Why is life-changing treatment so hard to access? Her story sheds light on the fight for affordable, consistent care—and why it matters for so many others.
🎉 We are Now Officially a Certified Charitable Nonprofit Corporation 🎉
The GLP-1 Collective is now a certified nonprofit, working to make GLP-1 medications affordable and accessible. With nearly 20,000 signatures, support groups, educational tools, and more, we’re building a stronger community and fighting for lasting solutions.
How Compound Tirzepatide Changed My Life
Imagine struggling for years with your weight, battling conditions like PCOS and insulin resistance, only to find that every effort feels like a losing battle. For Dee, that was reality—until GLP-1 medications entered the picture and offered hope. In this heartfelt blog, Dee shares their incredible journey of losing 223 pounds, navigating the highs and lows of expensive brand-name medications, and discovering life-changing compounded Tirzepatide.
This isn’t just a weight loss story; it’s a story of resilience, self-discovery, and the fight for accessible healthcare. Click to read how Dee turned adversity into advocacy—and found a way to truly thrive.
My Journey with Tirzepatide
This story shares one mother’s journey with compounded Tirzepatide, a medication that has completely transformed her health and her family’s life. From overcoming joint pain and weight struggles to helping her son regain his energy and confidence, her experience shows just how important accessible treatments can be.
By sharing her experience, she’s shedding light on the challenges of affordability and access, and why it matters for so many families. We’re so grateful for her voice in this fight.
FDA Removes Tirzepatide from the Shortage List: What This Means
The FDA has removed Tirzepatide from the drug shortage list, setting a timeline that will limit access to compounded versions by February 2025. This decision could lead to similar restrictions on Semaglutide and underscores the urgent need for permanent, affordable solutions for GLP-1 medications.
Compounding pharmacies have provided critical access, but lasting options like FDA-approved generics, lower prices, or mandatory insurance coverage are essential to ensure patients can manage chronic conditions without barriers. This update highlights the growing urgency to secure accessible, affordable treatments for all.
We’re Attempting to Contact the FDA
One month into our fight for affordable GLP-1 medications, we’ve achieved over 14,000 signatures, raised $1,000, secured three media interviews, and shared dozens of powerful stories. Today, we took another step by contacting the FDA ahead of their decision on Tirzepatide, which could drastically impact access.
This fight is about lasting solutions—affordable access to Tirzepatide, Semaglutide also known as Wegovy, Mounjaro, Zepbound, and Ozempic. Join the movement, share the petition, and help us push for real change. Together, we’re making an impact!
Only One Week Left: The FDA's Decision Could Change Everything
In just three weeks, our petition for affordable GLP-1 medications has reached nearly 12,000 signatures and has been featured in two media articles, with more coverage on the way.
Let’s make this final week count—share the petition and help create real change!
From Anonymity to Advocacy: My Journey Fighting for Affordable Access to GLP-1s
What began as a personal fight for my health has grown into a national movement demanding affordable access to life-changing GLP-1 medications.
Read more about how this movement started and how it’s making an impact across the country. Together, we can keep pushing for real change.
Considering Compounded GLP-1 Medications
In response to the high demand and shortages of brand-name GLP-1 medications, compounded options for semaglutide (used in Ozempic/Wegovy) and tirzepatide (used in Mounjaro) have become available. These compounded medications often use the same active ingredients as the brand-name options and may be offered at a lower price.
GLP-1 Assistance Program and Savings Card Options
If you’re facing financial challenges or insurance coverage issues, assistance programs and savings cards can help reduce the cost of GLP-1 medications. These resources are designed to make treatment more affordable, whether you're uninsured, underinsured, or struggling with out-of-pocket expenses.
How to Navigate Insurance Barriers for GLP-1 Medications
Navigating the insurance process for GLP-1 medications can feel overwhelming, but with the right steps, you can overcome barriers and improve your chances of securing coverage. This guide provides a clear roadmap to help you work with your healthcare provider and insurance company to advocate for the treatment you need.
Talking to Your Doctor About GLP-1s (And What to Do If They Say No)
This guide empowers you to have informed, productive conversations with your doctor about GLP-1 medications. Whether you're seeking a prescription, navigating accessibility challenges, or exploring alternative treatment plans, this resource will help you ask the right questions and take charge of your health journey.
Exciting News: Our Petition was Featured in USA Today!
Our petition for affordable GLP-1 medications was featured in USA Today. With just eight days left, every signature and share helps us push for better access to these life-changing treatments. Join the movement and make a difference!
We’ve Got the Media’s Attention—This Is a Huge Step Forward!
Update on the fight for affordable access to GLP-1 medications, highlighting recent milestones, including a feature in Politico, USA Today, and a call for support to amplify the message before the upcoming deadline.
The FDA Postponed Their Decision: Here’s Why That’s Good News and How You Can Help
The FDA’s decision has been delayed until December 11, 2024, giving us a crucial window to build support. In just three days, over 6,500 signatures have been gathered.
Efforts are focused on raising awareness, engaging influencers, and amplifying personal stories to show the real impact of these medications. Support the movement by signing, donating, or sharing your story to push for affordable, lasting solutions.
Why Today’s FDA Decision Matters and What’s at Stake
This fight is about more than medications—it's about people’s health, dignity, and hope for a better future. Learn how the GLP-1 Collective is pushing back against Big Pharma, advocating for lasting solutions, and amplifying the voices of those whose lives have been transformed.
Update: FDA Decision Delayed to 12/11/2024 – Let’s Keep Fighting!
First Update: The Fight for Affordable GLP-1 Access
The FDA has delayed its decision to December 11, 2024. With just under a month to act, the GLP-1 Collective is gaining momentum, adding 500+ signatures in two days. This update outlines how you can help—through sharing, donating, telling your story, and engaging the media.
Together, we can fight for affordable GLP-1 medications and ensure the FDA hears our voices.
The GLP-1 Shortage Crisis: How the FDA and Big Pharma Are Leaving Us Scrambling
Recent FDA actions threaten to restrict access to these affordable options, forcing patients to face unaffordable brand-name prices or turn to unsafe sources.
This fight isn’t just about medications—it’s about people’s health, futures, and dignity. As compounding pharmacies battle to remain open, the stakes couldn’t be higher for patients relying on these treatments.